Abivax

Wittycell

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Neovacs

Vincent Serra

Géraldine Grouard-vogel

Noémie Caillot

Romain Bertrand

Pierre Bruhns

Eva Conde García

Laurent Reber

An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activity

The present invention relates to a method of preparation of &#x3b1;-galactosyl ceramides compounds of formula (I): comprising a step a) of glycosylation of a compound of formula (II): with a compound of formula (III): 

Method of preparation of alpha galactosyl ceramides compounds

The present invention relates to a vaccine composition comprising: &#x2014;at least one prophylactically active agent against influenza, and &#x2014;at least one adjuvant, said adjuvant being a derivative of a galactosylceramide, for use in the treatment of influenza.

Vaccine composition for use against influenza

The immunogenicity of vaccines is enhanced by co-administering a synthetic glycolipid, designated PBS-57, with the vaccine. PBS-57 has the ability to stimulate both a cell-mediated and humoral immune response. Co-administration of PBS-57 with a vaccine may be used in methods to stimulate one or more of a humoral immune response, a CD4+ T cell response, and a CD8+ cytotoxic T cell response.

Methods of enhancing adjuvaticity of vaccine compositions

The present invention relates to compounds consisting of glycolipids covalently bound to an antigen or a drug via a linker. The said compounds are able to induce a stronger immune response than a composition comprising separated glycolipids and antigen. The said compounds are also able to target drug to CD1d restricted cells.

Increase of immune response and targeting by antigens and/or drug linkage

Compositions comprising the compound of formula are provided herein. Also provided are methods of enhancing an immune response of a subject to an antigen by administering the antigen and the composition. The enhanced immune response may be an humoral immune response, a CD4+ T cell response, a CD8+ T cell response or result in activation of antigen presenting cells. Methods of enhancing the immune response by intramuscular administration of an antigen and the composition including the compound of formula I are also provided.

Growing community of inventors

Bondoufle, France

Vincent Serra